Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas

Neuro-Oncology

Volumn 16, Issue 12, 2014, Pages 1645-1651

  Thaler, Johannes ^a   Ay, Cihan ^a   Kaider, Alexandra ^a   Reitter, Eva Maria ^a   Haselböck, Johanna ^a   Mannhalter, Christine ^a   Zielinski, Christoph ^a   Marosi, Christine ^a   Pabinger, Ingrid ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarkers; High grade gliomas; Prediction; Risk assessment models; Venous thromboembolism

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; D DIMER; PADGEM PROTEIN; PROTHROMBIN; PROTHROMBIN FRAGMENT 1; PROTHROMBIN FRAGMENT 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLIOMA; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PREDICTOR VARIABLE; PROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM; BLOOD; CENTRAL NERVOUS SYSTEM TUMOR; COMPLICATION; FOLLOW UP; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET COUNT; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84935457761     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou106     Document Type: Article

References (44)

1. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer. 2000;89(3):640-646.
2. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer. 1997;33(10):1592-1596.
3. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007;9(2):89-95.
4. Rodas RA, Fenstermaker RA, McKeever PE, et al. Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg. 1998;89(2):200-205.
5. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983;13(3):334-336.
6. Dhami MS, Bona RD, Calogero JA, et al. Venous thromboembolism and high grade gliomas. Thromb Haemost. 1993;70(3):393-396.
7. Streiff MB, Segal J, Grossman SA, et al. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 2004;100(8):1717-1723.
8. Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost. 2010;8(2):221-227.
9. Sciacca FL, Ciusani E, Silvani A, et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res. 2004;10(4):1312-1317.
10. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - Risk scores and recent randomised controlled trials. Thromb Haemost. 2012;108(6):1042-1048.
11. Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol. 2009;29(3):332-336.
12. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-609.
13. Shapiro WR, Shapiro JR. Biology and treatment of malignant glioma. Oncology (Williston Park). 1998;12(2):233-240. discussion 240, 246.
14. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
15. Preusser M, De Ribaupierre S, Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol. 2011;70(1):9-21.
16. Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost. 2011;9(Suppl 1):316-324.
17. Sjoblom L, Hardemark HG, Lindgren A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke. 2001;32(11):2567-2574.
18. Ay C, Jungbauer LV, Sailer T, et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem. 2007;53(7):1235-1243.
19. Vormittag R, Simanek R, Ay C, et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol. 2009;29(12):2176-2181.
20. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 2010;8(1):114-120.
21. Kanz R, Vukovich T, Vormittag R, et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost. 2010;9(19):57-63.
22. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 2012;10(7):1363-1370.
23. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703-2708.
24. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011;29(15):2099-2103.
25. Tiedje V, Dunkler D, Ay C, et al. The role of fibrinogen plasma levels, the -455G. A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. Thromb Haemost. 2011;106(5):908-913.
26. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27(25):4124-4129.
27. Rintelen C, Mannhalter C, Ireland H, et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol. 1996;93(2):487-490.
28. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association. 1999;94(446):496-509.
29. Hocking RR. The analysis and selection of variables in linear regression. Biometrics. 1976;32:1-49.
30. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 2010;8(1):114-120.
31. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
32. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996;88(9):3259-3287.
33. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004;92(3):459-466.
34. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA. 1996;93(21):11877-11882.
35. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359(6398):848-851.
36. Frenette PS, Johnson RC, Hynes RO, et al. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA. 1995;92(16):7450-7454.
37. Chong BH, Murray B, Berndt MC, et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994;83(6):1535-1541.
38. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34-45.
39. Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyteendothelial and leukocyte-platelet interaction. Thromb Haemost. 1999;81(1):1-7.
40. Anderson FA Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):19-16.
41. Zou JP, Morford LA, Chougnet C, et al. Human glioma-induced immunosuppression involves soluble factor (s) that alters monocyte cytokine profile and surface markers. J Immunol. 1999;162(8):4882-4892.
42. Kanz R, Vukovich T, Vormittag R, et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost. 2011;9(1):57-63.
43. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277(16):1305-1307.
44. Thaler J, Ay C, Pabinger I. Clinical significance of circulating microparticles for venous thromboembolism in cancer patients. Hamostaseologie. 2011;32(2):127-131.